This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Webinar series - Part 2 of 3.

The mechanisms and effects of COPD exacerbations.


Summary:

Our speaker Tracy Kirk will present a 3-part webinar series discussing Primary Care Based Medicine for Admissions Avoidance in COPD Patients.

Over the series, Tracy will explore various topics ranging from:
 The 'treatable traits' paradigm and essential components of this approach.
 The mechanisms and effects of COPD exacerbations
 Individualised treatment interventions

The on-demand video entitled The Mechanisms and effects of COPD exacerbations is the second webinar in the series.

Speaker

NA

Tracy Kirk

Director of Education for Primary Care Respiratory Training
Centre (PCRTC) Ltd. and Primary Care Diabetes Training
Centre (PCDTC) Ltd.

Tracy has been involved in Practice Nurse education since 2002 starting out as a tutor for the Practice Nurse Specialist Practitioner BSc Course at Manchester University before moving on to specialise in respiratory disease education. She has also worked as an assessor for the RCN Nurse Education Accreditation Unit.
For the past 20+ years, Tracy has been working on large scale Primary Care based Asthma, COPD and Diabetes projects across the UK and draws upon her vast experience within real-life general practice to develop the content of all the PCRTC/PCDTC programmes of learning.
Being at the ‘Coal Face’ has enabled hands on experience where she has personally reviewed 10,000+ patients who have had multiple unplanned admissions, 1000+ who have had repeated pneumonia admissions.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441